''Bayer Schering Pharma AG, Berlin, Germany, announced today that the Food and Drug Administration (FDA) has accepted for filing a New Drug Application to the U.S. for gadobutrol injection, a gadolinium-based contrast agent for magnetic resonance ...'
Wednesday, 4 August 2010 by viva.vita.bayerhealthcare.de
''Gadovist/Gadograf 1.0 mmol/ml contains gadobutrol, a neutral macrocyclic gadolinium (Gd) complex with contrast-enhancing properties, which is used for magnetic resonance imaging (MRI). MRI is a widely used technique for the evaluation and detection of ...'
•
News
top
